MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Dermatology and Skin Diseases
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,536 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,536 works in the cohort · of 4,299,418page 8 of 51

Labels cover 6 of 2,536 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,536 of 2,536 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase <scp>IIa</scp> study
Robert Bissonnette, William Abramovits, Étienne Saint‐Cyr Proulx, Patricia Lee, Emma Guttman‐Yassky, Elizabeta Zovko +3 more
2022· article· en· Journal of the European Academy of Dermatology and Venereology· Medicine
machine prediction:candidate · noneconsensus · none
43
citations
affno abstractunlabeled
The multidimensional burden of atopic dermatitis
Alanna C. Bridgman, Julie Block, Aaron M. Drucker
2018· review· en· Annals of Allergy Asthma & Immunology· Medicine
machine prediction:candidate · noneconsensus · none
43
citations
affunlabeled
Diagnosis and treatment of pruritus.
Dominik Alex Nowak, Jensen Yeung
2017· article· en· PubMed· Medicine
machine prediction:candidate · noneconsensus · none
42
citations
venueno affunlabeled
New Developments in Magnetic Resonance Imaging of the Nail Unit
Ernesto Soscia, Cesare Sirignano, Onofrio A. Catalano, Mariangela Atteno, Luisa Costa, Francesco Caso +6 more
2012· article· en· Journal of Rheumatology Supplement· Medicine
machine prediction:candidate · noneconsensus · none
40
citations
venueno affunlabeled
Pain and Itch Are Dual Burdens in Atopic Dermatitis
Melody Maarouf, Bryan Kromenacker, Korey Capozza, Darren Kempton, Aleksi J. Hendricks, Khiem A. Tran +1 more
2018· article· en· Dermatitis· Medicine
machine prediction:candidate · noneconsensus · none
39
citations
affunlabeled
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Jonathan I. Silverberg, Melinda Gooderham, Amy S. Paller, Mette Deleuran, Christopher G. Bunick, Linda Stein Gold +10 more
2024· article· en· American Journal of Clinical Dermatology· Medicine
machine prediction:candidate · noneconsensus · none
37
citations

How this was built: Screen · Findings · About